Selenium Sulfide

OXFORD, United Kingdom, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces a publication in Elsevier’s prestigious biomedical sciences journal Pharmacological Research. The work led by collaborators at Jagiellonian University Medical College showed that in a preclinical mouse study involving high-fat diet (HFD)-induced obesity, the company’s mtH2SD compound AP39, significantly slowed the rate of gain in weight. This is the first comprehensive study designed to test whether mitochondrial sulfide donors could address weight gain and fatty liver (steatosis). Mounting evidence suggests that hydrogen sulfide is an important signalling molecule in the liver, regulating lipid metabolism and mitochondrial function, but its direct delivery to mitochondria had not been investigated as a therapeutic strategy in obesity-related metabolic disorders. This is what the Pharmacological Research paper examined. MitoRx’s CSO, Prof Matt Whiteman, and their Senior Discovery Chemist, Dr. Roberta Torregrossa, with co-inventor Dr. Mark Wood at the University of Exeter are co-authors on the paper. It showed that treatment with AP39 reduced weight gain in animals fed HFD by 32% at the end of the research. (1) AP39 is a versatile mtH2SD tool compound that mediates very large and statistically significant reductions in liver steatosis, large and significant reductions in triglycerides, reductions in de novo lipogenesis, reductions in inflammatory markers, and significant downregulation of known liver proteomic markers of weight gain and the development of obesity, indicating mtH2SD-mediated downregulation mTOR/SREBP-1/SCD1 pathway alleviates obesity. MitoRx is developing undisclosed next-generation mtH2SDs to take to the clinic. Importantly, this modality is both muscle protective including in a severe fibrotic muscle atrophy model and is also anti-obesogenic. With this double therapeutic benefit, MitoRx’s next-gen mtH2SDs could potentially address the loss of lean muscle mass which is a serious side effect of marketed GLP-1 receptor agonist drugs in general, especially with age. This approach could be applicable in sarcopenic (age-related muscle mass and strength loss) obesity while also addressing muscle wasting in obese patients in general. Dr. Jon Rees, Chief Executive Officer of MitoRx, said: “MitoRx is advancing its first-in-class mitochondriotropic platform initially focused on myopathies and is now applying it to obesity offering a small molecule anti-obesogenic which is also muscle protective. This latest publication provides solid pre-clinical evidence that AP39 substantially suppressed the gain of weight in HFD-fed animals, suggesting a new pathway to alleviate obesity, whilst avoiding the muscle wasting side-effects that blight GLP-1 receptor agonist drugs. Powerful international research collaborations like this, with the talented team at Jagiellonian University’s Faculty of Medicine, help speed therapeutic advances to patients.” Dr. Aneta Stachowicz, Department of Pharmacology at the Faculty of Medicine, Jagiellonian University Medical College, Poland, and lead author of the Pharmacological Research paper, said: “Having comprehensively demonstrated that mitochondrial-targeted sulfide donors alleviate weight gain and significantly reduce multiple markers of obesity, we mark the beginning of a new era in the development of an innovative therapeutic approach for metabolic disease through the modulation of mitochondrial sulfide-signalling.” Matt Whiteman, Professor of Experimental Therapeutics at the University of Exeter Medical School, UK, and co-author of the study added: We discovered impaired sulfide metabolism in overweight patients with type 2 diabetes in 2010 (2) and we noticed that this impairment was driven by the amount of fat tissue these individuals were carrying; an observation since confirmed by many others. These findings suggested that treating this impairment with mtH2SD could potentially treat diabetes, obesity and complications arising from having too much fat in the body. It is gratifying to now translate those observations toward clinically viable drugs with MitoRx References: (1): Mitochondria-targeted hydrogen sulfide donor reduces fatty liver and obesity in mice fed a high fat diet by inhibiting de novo lipogenesis and inflammation via mTOR/SREBP-1 and NF-Kappa-B signaling pathways. Pharmacological Research 209 (2024):107428https://doi-org.libproxy1.nus.edu.sg/10.1016/j.phrs.2024.107428 (2): Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 53(8):1722-6 (2010). https://doi-org.libproxy1.nus.edu.sg/10.1007/s00125-010-1761-5 Company Contact (MitoRx) Jon Rees, CEOEmail: jon.rees@mitorxtherapeutics.com Phone: +44(0)7826 556622 Media Contact (Scius Communications for MitoRx) Katja Stout, Managing PartnerEmail: katja@sciuscommunications.com Phone: +44(0)7789 435990 University of Exeter Press Office  +44 (0)1392 722405 or 722062pressoffice@exeter.ac.uk Jagiellonian University Marcin Kubatrzecznik@uj.edu.pl About MitoRx TherapeuticsAt MitoRx our mission is to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction. We are a preclinical stage biotechnology company developing our first-in-class first-in-target, mitochondriotropic therapeutics in obesity-related indications and myopathies. Located in Harwell, Oxford, we have raised £5.4m seed financing from investors including the UK Innovation & Science Seed Fund, the Fink Family Office, Oxford Technology Management, Empirical Ventures, Wren Capital and Longevitytech.fund, as well as angel investors. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn. About the University of ExeterThe University of Exeter is a Russell Group university that combines world-class research with high levels of student satisfaction. Exeter has over 30,000 students and sits within the Top 15 universities in The Complete University Guide 2025, and tenth in the world in the Times Higher Education (THE) Impact Rankings. In the 2021 Research Excellence Framework (REF), more than 99% of our research were rated as being of international quality, and our world-leading research impact has grown by 72% since 2014, more than any other Russell Group university.https://www.exeter.ac.uk/ About Jagiellonian University The Jagiellonian University is the oldest higher education institution in Poland and one of the oldest in Europe. It was founded on 12 May 1364 by the Polish king Casimir the Great. The Jubilee year 2014 marked the 650th anniversary of this remarkable event. Since its very beginning, the Jagiellonian University has been an international institution. Today, the Jagiellonian University comprises 16 Faculties, where nearly 4 thousand academic staff conduct research and provide education to over 40 thousand students, within the framework of more than 80 different fields of study. The eminent researchers and state-of-the-art infrastructure make the JU one of the leading Polish scientific institutions, collaborating with major academic centres from all over the world. The Jagiellonian University is also home to about 150 student societies, where young researchers pursue their academic interests and develop friendships with people who share their passion. For more information visit our website at https://en.uj.edu.pl/en.

据估计，全球有超过13亿人患有皮肤病，其中我国皮肤病患者约有3.5亿人，约占全国人口的25%。有文献报道，新冠与甲流感染也会诱发皮肤病，发病率甚至高达20.5%，再加上快节奏时代来临，年轻人逐渐养成了熬夜、饮食不当等习惯，这使得我国皮肤病发病率逐年上升，皮肤病用药市场规模也在不断增容。皮肤用药总体市场情况从图1可以看出，我国皮肤用药市场规模呈逐年扩增趋势，2023年皮肤用药总销售额达到142.22亿元，同比2022年增长了14.61%。从图2可以发现，夏季仍然为皮肤用药的旺季，Q2-Q3的销售额居于前列，但是Q1的同比增长率出现高峰，说明2023年年初发生的甲流大规模感染给皮肤病患者带来了极大的影响。图1：2019-2023皮肤科用药市场销售额/年度同比增长率%数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心图2：2023Q1-202Q43皮肤用药市场销售额/季度同比增长率%数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心皮肤用药各品类市场占比在2023年皮肤用药领域中，外用抗感染制剂占比26.16%，排名第一，其热门品种包括莫匹罗星软膏、硝酸益康唑喷雾剂、盐酸特比萘芬喷雾剂等，全年销售额达到38.4亿元；其次是抗银屑病药，占比17.61%，排名第二；外用皮质激素制剂占比15.49%，排名第三。图3：2023年皮肤科用药市场各品类金额占比图数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心表1：2023年皮肤用药市场各品类金额数据数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心皮肤用药TOP 10药品从产品层面上看，司库奇尤和度普利尤这两款单抗注射液类药物的销售额占比较大，其余外用药中，复方酮康唑发用洗剂、莫匹罗星软膏和糠酸莫米松乳膏位列前三，具体金额如图表所示。图4：2023年皮肤科用药市场各产品金额占比图数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心表2：2023年皮肤科用药市场各产品金额数据数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心而排除单价影响，我们发现，最畅销的皮肤用药当属红霉素软膏，其2023全年销售量达到5342万支，市场占比8.17%，复方醋酸地塞米松乳膏和复方酮康唑发用洗剂紧随其后。图5：2023年皮肤科用药市场各产品包装数量占比图数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心表3：2023年皮肤科用药市场各产品包装数量数据数据来源：RPDB药品零售数据库-样本药店放大整体市场数据，中国医药工业信息中心网上药店除此之外，淘宝/天猫和京东的店铺数据同样不可忽视，数据显示：2023年网上药店皮肤科用药销售总额达到47.74亿元，其中Q4时期需求量增多，达到全年最高峰值。图6：2023Q1-2023Q4皮肤科用药网上药店市场销售额/季度同比增长率%数据来源：RPDB药品零售数据库-网上药店整体市场数据，中国医药工业信息中心与线下药店不同的是，网上药店中最畅销的皮肤用药产品为米诺地尔酊，全年总销售额为11.3亿，占比23.71%。网上药店中销量前十的产品依次为米诺地尔酊、联苯苄唑溶液、盐酸阿莫罗芬搽剂、米诺地尔搽剂、二硫化硒洗剂、阿达帕林凝胶、酮康唑洗剂、复方酮康唑发用洗剂、盐酸特比萘芬喷雾剂、甲硝唑凝胶。图7：2023年皮肤科用药网上药店市场各产品金额占比图数据来源：RPDB药品零售数据库-网上药店整体市场数据，中国医药工业信息中心RPDB是国内样本覆盖药店数最多的药品零售信息平台，监测全国30个省级行政区300多个城市的样本药店数据，各销售规模的门店均有覆盖，月度更新零售终端的药品销售区域、品类、产品特性、价格、运营数据、营销手段和消费者特征等核心信息，以及京东、天猫等主要线上渠道的药品销售数据。想获知更具体的药品零售市场销售数据，欢迎您进一步了解中国医药工业信息中心RPDB中国药品零售数据服务。END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001